Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?

Should we be more cautious with the use of GLP-1 receptor agonist therapy in patients with Type 1 diabetes mellitus and obesity, given the increased risk of cardiovascular disease with high body weight variability?

• No, the evidence suggests that the cardiovascular benefits of GLP-1 RA seen in patients without diabetes (e.g., the SELECT trial) should still apply to patients with Type 1 diabetes
• No, while the glucose control benefits in Type 1 diabetes have been less clear in smaller trials, these studies did not focus on cardiovascular outcomes, which may still be beneficial
• Yes, given the increased risk of cardiovascular disease associated with high body weight variability, more caution is warranted in using GLP-1 RA therapy in this population
• Other